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SmadIdiopathic pulmonary ﬁbrosis (IPF) is a chronic progressive lung disease of unknown cause that typically leads to
respiratory failure and deathwithin 3–5 years of diagnosis. TGF-β1 is considered amajor proﬁbrotic factor. Howev-
er, TGF-β1 is necessary but not sufﬁcient to the pathogenesis ofﬁbrotic lesion of the lungs. Recent observations have
revealed that calpain, a calciumdependent protease, plays a pivotal role in tissue remodeling andﬁbrosis. However,
the mechanism of calpain mediating pulmonary ﬁbrosis is not understood. Calpain conditional knockout (ER-
Cre+/−capns1ﬂox/ﬂox) mice and primary human lung ﬁbroblasts (HLFs) were used here to investigate the relation-
ship between calpain and TGF-β1. Calpain knockout mice were protected from ﬁbrotic effects of bleomycin.
Bleomycin induced increases in TGF-β1 via calpain activation in HLFs. Moreover, TGF-β1 also activated calpain.
This crosstalk between calpain activation and TGF-β1 triggered the downstream signaling pathway including
TGF-β1 Smad2/3 and non-Smad (Akt) pathways, as well as collagen-I synthesis. Taken together, our data indicate
that the crosstalk between calpain activation and TGF-β1 augments collagen-I synthesis in HLFs and in pulmonary
ﬁbrosis. Intervention in the crosstalk between calpain activation and TGF-β1 is a novel potential strategy to prevent
pulmonary ﬁbrosis.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Idiopathic pulmonary ﬁbrosis (IPF) is a chronic progressive lung
disease of unknown cause that typically leads to respiratory failure
and death within 3–5 years of diagnosis [1]. There are no effective thera-
pies yet for IPF. The pathological feature of IPF includes ﬁbroproliferative
foci and depositions of extracellular matrix (ECM). In IPF, myoﬁbroblasts
are hallmark and prominent components in ﬁbroproliferative foci. Many
different cell types have been suggested to be able to transdifferentiate
into the activated ﬁbroblasts and myoﬁbroblasts. These cells include
type I and II alveolar epithelial cells [2–4], resident ﬁbroblasts [5],
blood-borne ﬁbrocytes [6], pericytes [5] and pleural mesothelial cellss, human lung ﬁbroblasts; ECM,
t assay; p-Akt, phosphorylated-
; t-Smad2/3, total-Smad2/3
ngji Medical College, Huazhong
, Wuhan, Hubei 430030, China.
. This is an open access article under[7,8]. Hung and colleagues recently reported that pericytes and resident
ﬁbroblasts are the major sources of myoﬁbroblasts in pulmonary ﬁbrosis
[5]. However, studies by Jason and colleagues excluded pericytes and
the two types of alveolar epithelial cells as the origin of myoﬁbroblasts
[9]. Thus, there is agreement that resident ﬁbroblasts contribute to
myoﬁbroblasts in ﬁbrosis, but the role of other cell types is controver-
sial. The resident ﬁbroblasts turn into myoﬁbroblasts which produce
excessive extracellular matrix components, especially collagen-I [10].
Pulmonary ﬁbrosis induced bymultiple doses of bleomycin by intra-
peritoneal injection exhibits a chronic ﬁbrotic state and subpleural
ﬁbrotic distribution similar towhat is seen in human IPF [11]. This animal
model has been widely used in the studies of pulmonary ﬁbrosis.
Although the mechanism of pulmonary ﬁbrosis is not fully understood,
TGF-β1 is considered a major proﬁbrotic factor. However, TGF-β1 is nec-
essary but not sufﬁcient for the pathologic ﬁbrosis of the lungs [12]. Thus,
other proﬁbrotic factors, especially ones which interact with TGF-β1,
have been investigated in recent years.
Calpain is a calcium-dependent non-lysosomal neutral cysteine
endopeptidase. Our previous study revealed that calpain plays a pivotalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and colleagues reported that a calpain inhibitor prevents bleomycin-
induced pulmonary ﬁbrosis in mice [14]. However, the mechanism of
calpain mediating pulmonary ﬁbrosis is poorly understood. We have
previously shown that calpain mediates pulmonary vascular remodeling
via an intracrine TGF-β1 pathway [13]. Consistently, Letavernier et al.
demonstrated that calpain inducesmyocardialﬁbrosis partly by activat-
ing TGF-β [15]. On the other hand, Xie and colleagues found that TGF-β1
induces calpain activation in eosinophils [16], but this had not been de-
scribed in ﬁbroblasts. Our preliminary experiments found TGF-β1 in-
creased calpain activity in lung ﬁbroblasts. We therefore hypothesized
that there is crosstalk between calpain activation and TGF-β1, which
augments collagen-I synthesis in lung ﬁbroblasts contributing to the
pathogenesis of pulmonary ﬁbrosis. In the present study, we used
calpain knockout mice and primary lung ﬁbroblasts, and determined
the relationship between calpain and TGF-β1 aswell as their role in pul-
monary ﬁbrosis.
2. Materials and methods
2.1. Materials and reagents
Enzyme-linked immunosorbent assay (ELISA) kit for TGF-β1, and
TGF-β1 receptor inhibitor (SB431542) were obtained from R&D
Systems (Minneapolis, MN, USA). The calpain inhibitor MDL28170,
and ﬂuorogenic peptide Suc-Leu-Leu-Val-Tyr-AMC were purchased
from Calbiochem (La Jolla, CA, USA). Anti-calpastatin antibody,
hydroxyproline and TGF-β1 were obtained from Sigma-Aldrich Corp.
(St. Louis, MO, USA). Anti-collagen-I antibody was obtained from Novus
Biologicals (Littleton, CO, USA). Antibodies against phosphorylated-Akt
(p-Akt), total-Akt (t-Akt), total-Smad2/3 (t-Smad2/3) and GAPDH were
purchased from Cell Signaling Technology (Danvers, MA, USA). Antibody
against phosphorylated-Smad2/3 (p-Smad2/3) was purchased from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Antibodies against
α-Tubulin were purchased from Anbo Biotechnology (San Francisco,
CA, USA). Antibodies against CAPN1, CAPN2, and CAPNS1 were obtained
from Epitomics (Burlingame, CA, USA). Antibody against calretinin was
purchased from BD Transduction Laboratories (Lexington, KY, USA).
Bleomycin was obtained from Tianjin Taihe Pharmaceutical Co., Ltd
(Tianjin, China).
2.2. Conditional knockout of calpain in mice
The ubiquitously expressed calpain-1 and calpain-2 isoforms consist
of capn1- and capn2-encoded catalytic subunits, respectively, and an
obligate common regulatory unit encoded by capns1. Because the
capns1-encoded regulatory subunit is required for the activity of both
calpain-1 and -2, its genetic deletion results in loss of both calpains.
The targeted germline disruption of capns1 is embryonically lethal at
midgestation [17]. Therefore, we took advantage of the homozygous
mice targeted with ﬂoxed capns1 alleles (capns1ﬂox/ﬂox) [18] to cre-
ate conditional knockout mice of calpain-1 and -2. We used these
capns1ﬂox/ﬂox mice and B6.Cg-Tg (CAG-cre/Esr1) 5Amc/Jmice to gener-
ate ER-Cre+/−capns1ﬂox/ﬂoxmice as previously described by us [13]. PCR
was used to genotype the mice. Deletion of capns1 was induced by
administering tamoxifen (20 mg/kg/day, i.p.) for 5 days and was
conﬁrmed by analysis of CAPNS1, CAPN1 and CAPN2 using Western
blotting of lung tissues. Control mice were littermate capns1ﬂox/ﬂox or
capns1ﬂox/+ mice treated with the same tamoxifen regimen. Mice
8 weeks of age were used for the pulmonary ﬁbrosis model.
2.3. Pulmonary ﬁbrosis animal model
The study protocols in this study were approved by the Institutional
Animal Care and Use Committee of Tongji Medical College, Huazhong
University of Science and Technology. Pulmonary ﬁbrosis was inducedby bleomycin as previously described in our study [19]. Brieﬂy, mice
were housed under standard conditions with free access to water and
rodent laboratory food. Bleomycin dissolved in saline solution (concen-
tration, 5 mg/ml) was administered by intraperitoneal injection at a
dose of 50 mg/kg at days 1, 5, 8, 11, and 15, respectively. In the control
group, saline solutionwithout bleomycinwas administered by intraper-
itoneal injection at the same time. Two sub-group mice (bleomycin-
treated control mice) were euthanized at days 14 and 28, and lung
tissues were taken for detecting calpain activity. Other mice were
euthanized at day 40, and then lung tissues were taken for protein,
histological, and calpain activity analysis, and immunoﬂuorescence
staining.
2.4. In vivo administration of TGF-β1
2 μg/ml TGF-β1 were injected intravenously at 10 ng/g body weight
to C57BL/6J mice by tail intravenous injection once a day for 3 days.
Mice were euthanized at day 4, the left lung was excised and homoge-
nized, calpain activity was measured as described in measurement of
calpain activity in lung tissues.
2.5. Human lung ﬁbroblasts (HLFs) culture and treatment
HLFs were purchased from the Type Culture Collection of the
Chinese Academyof Sciences (Shanghai, China). TheHLFswere cultured
in Ham's F-12Kmedium (Life Technologies, Grand Island, NY, USA) sup-
plemented with 10% fetal calf serum and 5% CO2, 95% air at 37 °C. The
cells were subcultured 1:3 when they reached conﬂuence, and the cul-
turemediumwas changed every 2 days. Cells equilibrated in serum free
medium overnight were used for all experiments. Then the cells were
treated with or without inhibitors for the time periods indicated.
2.6. Western blot analysis
The cell lysates (10–20 μg of protein)were denatured and electropho-
resed on SDS-PAGE gels. Separated proteins were electro-transferred to
nitrocellulose membranes. The membranes were incubated with 5% fat-
free milk for 1 h, and then incubated with antibodies against collagen-I
(dilution 1:1000), p-Smad2/3 (dilution 1:100), t-Smad2/3 (dilution
1:1000), p-Akt (dilution 1:1000), t-Akt (dilution 1:1000), TGF-β1 (dilu-
tion 1:100), GAPDH (dilution 1:8000) orα-Tubulin (dilution 1:500) over-
night at 4 °C, and then washed with 0.1% Tween-20, 20 mM Tris-HCl
(pH 7.5) and 150mMNaCl (TTBS) three times for 10min. Secondary an-
tibody IgG conjugated to alkaline phosphatase was diluted in TTBS plus
5% fat-freemilk and incubatedwith themembranes at room temperature
for 1 h. Themembraneswerewashedwith TTBS and thendevelopedwith
Supersignal West Pico (Pierce, Rockford, IL, USA) for 3 min before expo-
sure to ﬁlm (Kodak, Rochester, NY, USA). Films were developed using
Kodak Medical X-ray processor 102 (Kodak, Rochester, NY, USA) to visu-
alize the reactive proteins followed by densitometric quantiﬁcation using
Image-Pro Plus software (Media Cybernetics, Rockville, MD, USA).
2.7. Measurement of calpain activity in HLFs
Calpain activity in HLFs wasmeasured using the ﬂuorogenic peptide
Suc-Leu-Leu-Val-Tyr-AMC as a substrate following the procedure de-
scribed previously [13]. Brieﬂy, the cells were cultured in 24-well plates.
After being washed twice with phosphate-buffered saline (PBS), Suc-
Leu-Leu-Val-Tyr-AMC was added to a ﬁnal concentration of 80 μM in
growth factor-free medium in the presence and absence of the calpain
inhibitor MDL28170. Immediately after addition of Suc-Leu-Leu-Val-
Tyr-AMC, ﬂuorescencewas recorded at 1min intervals for 30min at ex-
citation 360 nm and emission 460 nm using a Synergy 2 Multi-Mode
microplate reader (Biotek Instruments, Winooski, VT, USA). Calpain
activity was expressed by the ﬂuorescence unit in the absence of
MDL28170 subtracted from those in the presence of MDL28170.
1798 F.-Z. Li et al. / Biochimica et Biophysica Acta 1852 (2015) 1796–18042.8. Measurement of active TGF-β1 protein levels in HLFs
The protein levels of active TGF-β1 in HLFs were measured using an
ELISA kit from R&D Systems (Minneapolis, MN, USA) according to the
manufacturer's instructions.
2.9. Protein analysis in lung tissues
Protein levels of CAPNS1, CAPN1, CAPN2, calpastatin, collagen-I,
p-Smad2/3, t-Smad2/3, p-Akt, t-Akt, TGF-β1 andGAPDH in lung homog-
enates were measured using Western blot analysis as described above.
The monoclonal antibodies against CAPNS1 (dilution 1:1000), CAPN1
(dilution 1:1000), CAPN2 (dilution 1:5000), calpastatin (dilution
1:1000), p-Smad2/3 (dilution 1:1000), t-Smad2/3 (dilution 1:1000),
p-Akt (dilution 1:1000), t-Akt (dilution 1:1000), TGF-β1 (dilution
1:100), or GAPDH (dilution 1:8000) were used.
2.10. Measurement of calpain activity in lung tissues
Freshly dissected lung tissues were homogenized in sample buffer
(20mMTris-HCl, pH 7.5, 1mMEDTA, 1mMEGTA, 1mMdithiothreitol),
and frozen until use. The samples (100 μg of total protein) were mixed
with 150 μl of activity buffer (10 mM Tris–HCl, pH 7.5, 10 mM CaCl2,
0.1% β-mercaptoethanol) containing 100 μMof ﬂuorogenic calpain sub-
strate, Suc-Leu-Leu-Val-Tyr-AMC, and calpain activity was measured as
described above.
2.11. Hydroxyproline assay
To estimate total lung collagen content, hydroxyproline was mea-
sured as previously described with modiﬁcations [20]. The left lung
was homogenized in 300 μl lysis buffer (50 mM Tris–Cl, 15 mM NaCl,Fig. 1. Calpain knockout mice are protected from ﬁbrotic effects of bleomycin. (A) Lung tissue
CAPN1, CAPN2, calpastatin, p-Akt, p-Smad2/3 and GAPDH proteins by Western blotting. (B)
from Western blotting in (A) was determined by densitometry and normalized to GAPDH. Lu
(E). (D) Changes in calpain activity at different time-points in the lung tissues of control mice.
in the lung tissues according to F. (B, C, D, E, G) Data are expressed asmean± SEM, n=5 (cont
versus bleomycin group in control mice.pH 7.4) per 0.1 g lung tissue, and then hydrolyzed in 6 N HCl at 120 °C
for 12 h. After being neutralized with 6 N NaOH, 1 ml diluted aliquots
were added to 0.5 ml of 0.5 M sodium acetate (pH 6.0), and 1 ml of
0.05 M chloramine T. After incubating at room temperature for
20 min, 1 ml of 3.15 M perchloric acid was added and the mixture
was again incubated at room temperature for 5 min. After that, 1 ml
of 10% p-dimethylaminobenzaldehyde in 70% n-propanol was added,
followed by incubation at 60 °C for 20 min. Absorbance was measured
at 550 nm and the amount of hydroxyproline was determined against
a standard curve generated using known concentrations of reagent hy-
droxyproline. Hydroxyproline levels are presented asmg/g lung tissues.2.12. Histological analysis
Mouse lungs were removed and ﬁxed in 4% paraformaldehyde for
24 h. The ﬁxed lungs were then sliced mid-sagittally and embedded in
parafﬁn. The slides of 5 μm thicknesswere stainedwithMasson staining
for morphological analysis and evaluation of collagen deposition. The
slides were examined by using a microscope connected with a digital
camera and Image-Pro Plus software was used to analyze the images.2.13. Immunoﬂuorescence staining of lung tissue
Frozen mouse lung sections were ﬁxed with 4% paraformaldehyde
for 10 min at room temperature. The slides were incubated with anti-
bodies against CAPNS1 (dilution 1:100), CAPN1 (dilution 1:100),
CAPN2 (dilution 1:100), and TGF-β1 (dilution 1:50) for 1 h and then
withﬂuorescein isothiocyanate (FITC)-conjugated donkey anti-goat an-
tibody, or tetramethyl rhodamin isothiocyanate (TRITC)-conjugated
goat anti-rabbit antibody for 30 min. The nuclei were stained with
DAPI for 10 min in the dark. The slides were mounted with anti-fades from control mice and capns1 knockout (capns1 KO) mice were used to detect CAPNS1,
Changes in relative levels of CAPNS1, CAPN1, CAPN2, calpastatin, p-Akt, and p-Smad2/3
ng tissues were used to measure calpain activity (C), and hydroxyproline content
(F) Representative Masson staining of lung sections. (G) Changes in collagen percentages
rolmice), n= 3 (capns1KOmice). *P b 0.05 versus control group in control mice, #P b 0.05
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Olympus, Tokyo, Japan).
2.14. Statistical analysis
Results are shown as themean±SEM. Control and experimental cells
werematched for cell line, age, seeding density, number of passages, and
number of days post-conﬂuence. Differences between groups were ana-
lyzed using unpaired t tests or two-way analysis of variance. P value
less than 0.05 was considered to be statistically signiﬁcant.
3. Results
3.1. Calpain knockout (calpain KO) mice are protected from ﬁbrotic effects
of bleomycin
To investigate the role of calpain in pulmonary ﬁbrosis, the effect of
bleomycinwas studied in calpain KOmice. In the capns1 knockoutmice,
the levels of CAPNS1 protein (the obligate regulatory subunit of the
ubiquitously expressed calpain-1 and calpain-2 isoforms) in the lung
tissue were signiﬁcantly decreased (Fig. 1A and B), which are the cata-
lytic subunits of calpain-1 and -2, respectively. This was accompanied
by decreased expression of CAPN1 and a trend toward reduced CAPN2
(Figs. 1A, B, s1). The endogenous inhibitor of calpain, calpastatin did
not change in capns1 knockout mice compared with control mice
(Fig. 1A and B). At the same time, we detected calpain activity in the
lung tissues. As shown in Fig. 1C and D, calpain activity was increased
in the lung tissues of bleomycin-treated control mice at days 14, 28,Fig. 2. Calpain activationmediates bleomycin-induced collagen-I synthesis in human lung ﬁbro
calpain inhibitor (MDL28170, 0–100 μmol/l) for 24 h, afterwhich intracellular collagen-I protein
expressed asmean±SEM, n=3. *P b 0.05 versus control. (E–G)HLFswere incubatedwith bleo
intracellular calpain activity was detected according to themethod (E), collagen-I proteinswere
as mean ± SEM, n = 5. *P b 0.05 versus control, #P b 0.05 versus bleomycin.and 40. In contrast, bleomycin failed to induce an increase in calpain
activity in the capns1 knockout mice (Fig. 1C). A hydroxyproline assay
revealed that collagen levels were obviously increased in the lung
tissues of bleomycin-treated control mice (Fig. 1E). Knockout of
capns1 prevented over-deposition of collagen and pulmonary ﬁbrosis
(Fig. 1E, F, and G). As shown in Fig. 1A and B, bleomycin induced in-
creases in the phosphorylation (activation) of Smad2/3 and Akt, but
this was not observed in capns1 knockout mice. Collectively, these
data clearly demonstrate that the capns1 knockout mice are protected
from ﬁbrotic effects of bleomycin, and that Smad2/3 and Akt signaling
pathways may be involved in the ﬁbrotic process.
3.2. Calpain activationmediates bleomycin-induced collagen-I synthesis
in HLFs
The mediating role of calpain in collagen-I synthesis in pulmonary
vascular remodeling has been reported in our previous study [13]. To
evaluate whether calpain mediates collagen-I synthesis in HLFs and
pulmonary ﬁbrosis, we treated HLFs with different doses of bleomycin
(0–1.0 μg/ml) or calpain inhibitor (MDL28170, 0–100 μmol/l) andmea-
sured collagen-I protein levels. It revealed that bleomycin induced dose-
dependent increases in collagen-I synthesis in HLFs (Fig. 2A and B), and
MDL28170 suppressed bleomycin-induced collagen-I synthesis also in a
dose dependent manner (Fig. 2C and D). Then we treated HLFs with
0.2 μg/ml bleomycin in the absence or presence of MDL28170
(20 μmol/l), and measured calpain activity and intracellular collagen-I
protein levels. As shown in Fig. 2E, calpain activity was signiﬁcantly in-
creased by bleomycin. Bleomycin induced collagen-I synthesis in HLFs,blasts (HLFs). (A–D) HLFs were incubatedwith bleomycin (0–1.0 μg/ml) in the presence of
swere detected byWestern blotting (A, C), and quantiﬁed bydensitometry (B, D). Data are
mycin (0.2 μg/ml) for 24h in the absence or presence ofMDL28170 (20 μmol/l), afterwhich
detected byWestern blotting (F), and quantiﬁed by densitometry (G). Data are expressed
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suggest that bleomycin induces collagen-I synthesis via calpain activa-
tion in HLFs.3.3. Calpain activation by bleomycin mediates collagen-I synthesis via
TGF-β1 Smad and non-Smad (Akt) signaling pathway
Both TGF-β Smad and non-Smad signaling pathways have been
demonstrated in pulmonary ﬁbrosis. To explore the mechanism by
which calpain mediates collagen-I synthesis and pulmonary ﬁbrosis, p-
Smad2/3 and p-Akt were measured in HLFs treated with bleomycin for
24 h in the absence or presence of MDL28170. As shown in Fig. 3A-D,
bleomycin induced increases in the protein levels of p-Smad2/3 and
p-Akt in the absence of MDL28170. In the presence of MDL28170,
bleomycin did not change p-Smad2/3 and p-Akt protein levels.
MDL28170 also prevented phosphorylation of Smad2/3 or Akt in HLFs
treated with bleomycin at 0–60 min (Fig. s2). Then, we used the
TGF-β receptor inhibitor, SB431542 to block TGF-β1 signaling.
SB431542 prevented the increase in p-Akt (Fig. 3E and F), as well as
collagen-I synthesis (Fig. 3G and H) induced by bleomycin in HLFs.
These data suggest that calpain activation by bleomycin mediates
collagen-I synthesis via the TGF-β1 signaling pathway including
Smad2/3 and non-Smad PI3K/Akt pathway.Fig. 3. Calpain activation by bleomycinmediates collagen-I synthesis via TGF-β receptor-Smad2
the absence or presence of calpain inhibitor (MDL28170, 20 μmol/l), or TGF-β receptor inhibito
colllagen-I proteinsweremeasured byWestern blotting. (A, C, E, G) are representative images o
p-Akt, p-Akt, and collagen-I protein according to A, C, E, G, respectively. Data are expressed as m
bleomycin.3.4. Calpain mediates TGF-β1 synthesis and activation, and TGF-β1 activates
calpain in turn
To evaluate the role of bleomycin and calpain on TGF-β1 in pulmo-
nary ﬁbrosis, TGF-β1 expression in bleomycin-induced ﬁbrotic lung
tissues were analyzed by using immunoﬂuorescence staining and
Western blot analysis. As shown in Fig. 4A–C, bleomycin induced mag-
niﬁcent TGF-β1 expression in the lung tissues of control, but not capns1
knockoutmice. To further evaluate the role of bleomycin and calpain on
TGF-β1 synthesis and activation, HLFs treated with bleomycin in the
absence or presence ofMDL28170. As shown in Fig. 4D–F, bleomycin in-
duced increases in the levels of latent TGF-β1 and active TGF-β1 in the
absence of MDL28170. MDL28170 prevented the increases in the levels
of both latent TGF-β1 and active TGF-β1 induced by bleomycin. These
data suggest that calpain mediates bleomycin-induced TGF-β1 synthesis
and activation inHLFs. At same time, to investigate potential crosstalk be-
tween calpain activation and TGF-β1, HLFs were treated with TGF-β1,
and then calpain activity was measured. As shown in Fig. 4G, TGF-β1
induced an increase in calpain activity. To further conﬁrm the role of
TGF-β1 in calpain activation by bleomycin, the TGF-β receptor inhibitor
SB431542was used to block the TGF-β1 pathway. Bleomycin induced in-
creases in calpain activity were blocked by SB431542 in HLFs (Fig. 4H).
These data suggest that TGF-β1 also induces calpain activation in HLFs.
We did not ﬁnd additive or synergistic effect of bleomycin and TGF-β1/3 and -Akt signaling pathway. HLFswere incubatedwith bleomycin (0.2 μg/ml) for 24 h in
r (SB431542, 10 μmol/l), after which intracellular p-Smad2/3, t-Smad2/3, p-Akt, t-Akt, and
f immunoblots. (B, D, F, H) are bar graphs depicting changes in relative levels of p-Smad2/3,
ean ± SEM, (B, H) n= 3, (D) n = 5, (F) n = 4. *P b 0.05 versus control, #P b 0.05 versus
Fig. 4. Calpain mediates TGF-β1 synthesis and activation, and TGF-β1 activates calpain in turn. (A, B, C) Analysis of lung tissues from control mice and capns1 knockout (capns1 KO) mice.
(A) RepresentativeWestern blot of TGF-β1 proteins in lung tissues. (B) Changes in relative levels of TGF-β1 according to A. Data are expressed asmean± SEM, n=5 (controlmice), n=3
(capns1KOmice). *P b 0.05 versus control group in controlmice, #P b 0.05 versus bleomycin group in controlmice. (C) Representative images of immunoﬂuorescence staining of TGF-β1 in
lung sections. (D, E, F) HLFs were incubatedwith bleomycin (0.2 μg/ml) for 24 h in the absence or presence of calpain inhibitor (MDL28170, 20 μmol/l), after which intracellular latent TGF-β1
proteinsweremeasured byWestern blotting (D), and quantiﬁed by densitometry (E). The levels of active TGF-β1were detected by ELISA (F). (E, F) Data are expressed asmean± SEM, n=5.
*P b 0.05 versus control, #P b 0.05 versus bleomycin. (G) HLFswere incubatedwith TGF-β1 (5 ng/ml) for 24 h, afterwhich intracellular calpain activitywas detected according to themethods.
Data are expressed as mean ± SEM, n = 4. *P b 0.05 versus Control. (H) HLFs were incubated with bleomycin (0.2 μg/ml) for 24 h in the absence or presence of TGF-β receptor inhibitor
(SB431542, 10 μmol/l), after which intracellular calpain activity was detected. Data are expressed as mean ± SEM, n = 4. *P b 0.05 versus control, #P b 0.05 versus bleomycin. (I) Changes
in calpain activity in the lung tissues of control mice treated with TGF-β1 for 3 days. Data are expressed as mean ± SEM, n = 4. *P b 0.05 versus control.
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calpain activation in vivo, mice were directly treated with TGF-β1 for
3 days. As shown in Fig. 4I, TGF-β1 increased calpain activation in the
mouse lung tissues. Collectively, these results demonstrate that there is
crosstalk between calpain activation and TGF-β1 in HLFs and pulmonary
ﬁbrosis induced by bleomycin.3.5. Calpain mediates TGF-β1 Smad and non-Smad (Akt) signaling pathway
To further conﬁrm the role of crosstalk between calpain activation
and TGF-β1 in collagen-I synthesis, HLFs were directly treated with
TGF-β1 with or without the calpain inhibitor MDL28170. As shown in
Fig. 5A and B, TGF-β1 induced dose-dependent changes in collagen-I
synthesis without MDL28170. TGF-β1 increased p-Akt and p-Smad2/3
levels from 5 min to 60 min in the HLFs without MDL28170 pre-
treating (Fig. 5C, D, G, and H). In contrast, p-Smad2/3 just increased at
30 min, p-Akt increased mildly at 15 min and 30 min when HLFs
were pre-treated with MDL28170 for 3 h (Fig. 5E, F, I, and J). At 24 h,
TGF-β1 induced increases in the protein levels of p-Smad2/3 and p-Akt
as well as collagen-I, but this was blocked by MDL28170 (Fig. 5K–P).
These data suggest that TGF-β1 induces collagen-I synthesis and that
calpain activation mediates TGF-β1-Smad2/3 and -non-Smad (Akt)
pathway.4. Discussion
In this study, we demonstrated that the capns1 knockout mice are
protected from ﬁbrotic effects of bleomycin, and provided evidence
that Smad2/3 and Akt signaling of TGF-β1 pathways are involved in
the underlyingmechanism.We next askedwhether therewas crosstalk
between TGF-β1 and calpain activation that could eventually lead to
pulmonary ﬁbrosis. Our data presented in this study (Fig. 6) show that
bleomycin induces increases in TGF-β1 level via calpain activation in
the HLFs in vitro model. In turn, TGF-β1 also activates calpain. Thus, a
crosstalk between calpain activation and TGF-β1 triggers the down-
stream TGF-β signaling pathway. Both TGF-β1 Smad2/3 and non-
Smad (Akt) pathways are activated and mediate collagen-I synthesis
in HLFs. To the best of our knowledge, this is the ﬁrst report that the
crosstalk between calpain activation and TGF-β1 augments collagen-I
synthesis in HLFs as well as pulmonary ﬁbrosis.
Calpain is a family of calcium-dependent, non-lysosomal neutral
cysteine endopeptidases [21]. There are at least 15mammalian isoforms
in the family [22,23]. Calpain-1 and calpain-2 are two major typical
calpains. Calpain-1 and -2 consist of distinct catalytic subunits, encoded
by capn1 and capn2, respectively, and a common regulatory subunit
encoded by capns1 (previously known as capn4) that is required for ac-
tivity and stability of the catalytic subunits [22,23]. Thus, knockout of
capns1 results in inhibition of both calpain-1 and calpain-2 [17,18].
Fig. 5.Calpainmediates TGF-β1 Smad and non-Smad (Akt) signaling pathways. (A, B)HLFswere incubatedwith TGF-β1 (0–10ng/ml) for 24 h, afterwhich intracellular collagen-I proteins
weremeasured byWestern blotting (A), and quantiﬁed by densitometry (B). Data are expressed asmean± SEM, n= 3, *P b 0.05 versus Control. (C–J) HLFswere treatedwith orwithout
calpain inhibitor (MDL28170, 20 μmol/l) for 3 h, then treated with TGF-β1 (5 ng/ml) for 0–60 min, after which intracellular p-Smad2/3, t-Smad2/3, p-Akt, and t-Akt proteins were
measured by Western blotting (C, E, G, I), and quantiﬁed by densitometry (D, F, H, J). Data are expressed as mean ± SEM, n = 3, *P b 0.05 versus Control. (K–P) HLFs were incubated
with TGF-β1 (5 ng/ml) for 24 h in the absence or presence of MDL28170 (20 μmol/l), after which intracellular p-Smad2/3, t-Smad2/3, p-Akt, t-Akt, and collagen-I proteinsweremeasured
byWestern blotting (K,M, O), and quantiﬁed by densitometry (L, N, P). Data are expressed asmean± SEM, (L) n=4, (N) n=3, (P) n=5. *P b 0.05 versus Control, #P b 0.05 versus TGF-β1.
1802 F.-Z. Li et al. / Biochimica et Biophysica Acta 1852 (2015) 1796–1804Because capns1 was not absolutely deleted in these conditional knock-
out mice, CAPNS1, CAPN1 and CAPN2 are signiﬁcantly decreased, but
still show some expression. Our results show that knockout of capns1
prevents over-deposition of collagen as well as pulmonary ﬁbrosis in
the bleomycin in vivomousemodel.Maintenance of proper calpain activ-
ity level is essential for physiological functions, but over-activation of
calpain is harmful. In this study, administration of bleomycin in both
the animal model and in cultured HLFs induces an increase in calpain ac-
tivation, which leads to an increase in TGF-β1 activation in HLFs. Consis-
tentwith this interpretation, capns1 knockout results in lower expression
of TGF-β1 in the lung tissues of bleomycin-induced pulmonary ﬁbrosis.
Abe and colleagues reported that calpain binds to the cell surface via pro-
teoglycans and activates latent TGF-β1 by cleaving latency-associatedpeptides (LAPs) [24]. In addition, recent publications demonstrate that
intracellular calpain may activate the latent form of TGF-β1 in the cells
as well [13,25]. In the current study, we revealed that calpain mediates
TGF-β1 protein synthesis in the HLFs. Moreover, it has been reported
that calpain mediates dendritic protein synthesis in hippocampal tissues
and neurons [26], and induces higher expression of TNF-αmRNA and
protein in myocardial tissues [27]. Tabata and colleagues reported that
bleomycin induced increases of TGF-β1 mRNA, which was suppressed
signiﬁcantly by the administration of a calpain inhibitor [14]. Thus,
calpain can affect TGF-β1 both on the transcriptional level and the post-
translational level. Collectively, bleomycin-induced calpain activation
not only activates latent TGF-β1, but also mediates TGF-β1 protein syn-
thesis. On the other hand, TGF-β1 induces an increase in calpain activity,
Fig. 6. Crosstalk between calpain activation and TGF-β1 augments collagen-I synthesis in
pulmonary ﬁbrosis. Bleomycin induces increases in levels of TGF-β1 via calpain activation
in the HLFs. In turn, TGF-β1 also activates calpain. Subsequently, the crosstalk between
calpain activation and TGF-β1 triggers signaling to downstream TGF-β1 Smad2/3 and
non-Smad (Akt) pathways, as well as collagen-I synthesis.
1803F.-Z. Li et al. / Biochimica et Biophysica Acta 1852 (2015) 1796–1804and blockage of TGF-β1 signaling prevents bleomycin-induced calpain
activation. These results demonstrate that TGF-β1 in turn mediates
calpain activation. TGF-β1-treated cardiac ﬁbroblasts exhibit higher
levels of intracellular Ca2+ concentration ([Ca2+]i) [28]. Gao and
colleagues reported that TGF-β1 increases the basal [Ca2+]i level in air-
way smooth muscle cells [29]. Because calpain is a calcium-dependent
endopeptidase, TGF-β1-induced increase in [Ca2+]i provides a mecha-
nism responsible for the calpain activation by TGF-β1.
Smad2/3 is the classic downstream signal transducer of TGF-β1
which is the major proﬁbrotic factor. During the past two decades, it
has been ﬁrmly established that the Smad pathway is the pivotal signal
transduction from the receptors of the TGF-β superfamily members to
the nucleus. However, growing biochemical and developmental evi-
dence supports the notion that alternative, non-Smad pathways also
participate in TGF-β1 signaling [30]. The PI3K/Akt signaling pathway is
one of important non-Smad pathways and is one of themost important
pathways which are involved in protein synthesis and cell growth [31].
In the current study, increases in both p-Smad2/3 and p-Akt in
bleomycin-treated HLFs are prevented by the TGF-β receptor inhibitor.
This revealed that bleomycin triggers both TGF-β1 Smad and non-Smad
signalingpathways in theHLFs. Inhibition of calpain or the TGF-β receptor
prevents the increase in collagen-I which is one of themajor components
in ﬁbrotic lung tissues. This provides additional in vitro evidence that
calpain activation and TGF-β1 signaling are involved in pulmonary
ﬁbrosis.
It has been reported the therapeutic function of calpain inhibitor
[14]. Mice were treated with calpain inhibitor, calpeptin for the ﬁrst
14 days (days 0–14) or the last 14 days (days 14–28) in the
bleomycin-induced model. The administration of calpeptin for the ﬁrst
14 days or the last 14 days prevented bleomycin-induced pulmonary
ﬁbrosis equally (35.4% decrease, 31.3% decrease). SNJ-1945, a novel
water-soluble calpain inhibitor has been used in animal models to
treatmultiple sclerosis [32]. In our opinion, SNJ-1945 is a potentialmed-
ication for MS patients.
In conclusion, bleomycin induces calpain and TGF-β1 activation
which triggers TGF-β1 Smad and non-Smad signaling pathways via
TGF-β receptor. Crosstalk between calpain activation and TGF-β1
augments collagen-I synthesis in HLFs and pulmonary ﬁbrosis (Fig. 6).
Intervention in the crosstalk between calpain activation and TGF-β1
might be a novel potential strategy to treat pulmonary ﬁbrosis.Disclosure
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